Melanoma, version 2.2016 clinical practice guidelines in oncology

Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson, Gregory A. Daniels, Dominick DiMaio, Marc Ernstoff, Ryan C. Fields, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Richard W Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. Olszanski & 11 others Merrick I. Ross, April K. Salama, Joseph Skitzki, Jeff Sosman, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian, Anita Engh

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and highdose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted reassessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections.

Original languageEnglish (US)
Pages (from-to)450-473
Number of pages24
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume14
Issue number4
StatePublished - Apr 1 2016

Fingerprint

Practice Guidelines
Melanoma
Therapeutics
Intralesional Injections
Immunotherapy
Guidelines

ASJC Scopus subject areas

  • Oncology

Cite this

Coit, D. G., Thompson, J. A., Algazi, A., Andtbacka, R., Bichakjian, C. K., Carson, W. E., ... Engh, A. (2016). Melanoma, version 2.2016 clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 14(4), 450-473.

Melanoma, version 2.2016 clinical practice guidelines in oncology. / Coit, Daniel G.; Thompson, John A.; Algazi, Alain; Andtbacka, Robert; Bichakjian, Christopher K.; Carson, William E.; Daniels, Gregory A.; DiMaio, Dominick; Ernstoff, Marc; Fields, Ryan C.; Fleming, Martin D.; Gonzalez, Rene; Guild, Valerie; Halpern, Allan C.; Hodi, F. Stephen; Joseph, Richard W; Lange, Julie R.; Martini, Mary C.; Materin, Miguel A.; Olszanski, Anthony J.; Ross, Merrick I.; Salama, April K.; Skitzki, Joseph; Sosman, Jeff; Swetter, Susan M.; Tanabe, Kenneth K.; Torres-Roca, Javier F.; Trisal, Vijay; Urist, Marshall M.; McMillian, Nicole; Engh, Anita.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, No. 4, 01.04.2016, p. 450-473.

Research output: Contribution to journalArticle

Coit, DG, Thompson, JA, Algazi, A, Andtbacka, R, Bichakjian, CK, Carson, WE, Daniels, GA, DiMaio, D, Ernstoff, M, Fields, RC, Fleming, MD, Gonzalez, R, Guild, V, Halpern, AC, Hodi, FS, Joseph, RW, Lange, JR, Martini, MC, Materin, MA, Olszanski, AJ, Ross, MI, Salama, AK, Skitzki, J, Sosman, J, Swetter, SM, Tanabe, KK, Torres-Roca, JF, Trisal, V, Urist, MM, McMillian, N & Engh, A 2016, 'Melanoma, version 2.2016 clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 14, no. 4, pp. 450-473.
Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE et al. Melanoma, version 2.2016 clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2016 Apr 1;14(4):450-473.
Coit, Daniel G. ; Thompson, John A. ; Algazi, Alain ; Andtbacka, Robert ; Bichakjian, Christopher K. ; Carson, William E. ; Daniels, Gregory A. ; DiMaio, Dominick ; Ernstoff, Marc ; Fields, Ryan C. ; Fleming, Martin D. ; Gonzalez, Rene ; Guild, Valerie ; Halpern, Allan C. ; Hodi, F. Stephen ; Joseph, Richard W ; Lange, Julie R. ; Martini, Mary C. ; Materin, Miguel A. ; Olszanski, Anthony J. ; Ross, Merrick I. ; Salama, April K. ; Skitzki, Joseph ; Sosman, Jeff ; Swetter, Susan M. ; Tanabe, Kenneth K. ; Torres-Roca, Javier F. ; Trisal, Vijay ; Urist, Marshall M. ; McMillian, Nicole ; Engh, Anita. / Melanoma, version 2.2016 clinical practice guidelines in oncology. In: JNCCN Journal of the National Comprehensive Cancer Network. 2016 ; Vol. 14, No. 4. pp. 450-473.
@article{e554cd25081f4e56931f11930fcde100,
title = "Melanoma, version 2.2016 clinical practice guidelines in oncology",
abstract = "This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and highdose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted reassessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections.",
author = "Coit, {Daniel G.} and Thompson, {John A.} and Alain Algazi and Robert Andtbacka and Bichakjian, {Christopher K.} and Carson, {William E.} and Daniels, {Gregory A.} and Dominick DiMaio and Marc Ernstoff and Fields, {Ryan C.} and Fleming, {Martin D.} and Rene Gonzalez and Valerie Guild and Halpern, {Allan C.} and Hodi, {F. Stephen} and Joseph, {Richard W} and Lange, {Julie R.} and Martini, {Mary C.} and Materin, {Miguel A.} and Olszanski, {Anthony J.} and Ross, {Merrick I.} and Salama, {April K.} and Joseph Skitzki and Jeff Sosman and Swetter, {Susan M.} and Tanabe, {Kenneth K.} and Torres-Roca, {Javier F.} and Vijay Trisal and Urist, {Marshall M.} and Nicole McMillian and Anita Engh",
year = "2016",
month = "4",
day = "1",
language = "English (US)",
volume = "14",
pages = "450--473",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "4",

}

TY - JOUR

T1 - Melanoma, version 2.2016 clinical practice guidelines in oncology

AU - Coit, Daniel G.

AU - Thompson, John A.

AU - Algazi, Alain

AU - Andtbacka, Robert

AU - Bichakjian, Christopher K.

AU - Carson, William E.

AU - Daniels, Gregory A.

AU - DiMaio, Dominick

AU - Ernstoff, Marc

AU - Fields, Ryan C.

AU - Fleming, Martin D.

AU - Gonzalez, Rene

AU - Guild, Valerie

AU - Halpern, Allan C.

AU - Hodi, F. Stephen

AU - Joseph, Richard W

AU - Lange, Julie R.

AU - Martini, Mary C.

AU - Materin, Miguel A.

AU - Olszanski, Anthony J.

AU - Ross, Merrick I.

AU - Salama, April K.

AU - Skitzki, Joseph

AU - Sosman, Jeff

AU - Swetter, Susan M.

AU - Tanabe, Kenneth K.

AU - Torres-Roca, Javier F.

AU - Trisal, Vijay

AU - Urist, Marshall M.

AU - McMillian, Nicole

AU - Engh, Anita

PY - 2016/4/1

Y1 - 2016/4/1

N2 - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and highdose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted reassessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections.

AB - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and highdose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted reassessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections.

UR - http://www.scopus.com/inward/record.url?scp=84964355523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964355523&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 450

EP - 473

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 4

ER -